Skip to main content

Table 2 Clinical characteristics

From: Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

  Low-risk PV (n = 1033) High-risk PV (n = 1823) All patients (N = 2856)
Comorbid condition, n (%)
 Hypertension 445 (43.1) 1185 (65.0) 1630 (57.1)
 Chronic pain 187 (18.1) 473 (25.9) 660 (23.1)
 Diabetes (type 2) 104 (10.1) 396 (21.7) 500 (17.5)
 Osteoarthritis 102 (9.9) 366 (20.1) 468 (16.4)
 Cancer (excluding leukemia and MM) 66 (6.4) 381 (20.9) 447 (15.7)
 Gastroesophageal reflux disease 121 (11.7) 224 (12.3) 345 (12.1)
 Anemia 64 (6.2) 168 (9.2) 232 (8.1)
 Depression 81 (7.8) 123 (6.7) 204 (7.1)
 Anxiety 73 (7.1) 117 (6.4) 190 (6.7)
 Congestive heart failure 6 (0.6) 121 (6.6) 127 (4.4)
 Non-AML leukemia 5 (0.5) 14 (0.8) 19 (0.7)
 MM 1 (0.1) 8 (0.4) 9 (0.3)
Concomitant medication, n (%)
 Cardiovasculara 636 (61.6) 1526 (83.7) 2162 (75.7)
 Corticosteroid (oral or IV) 306 (29.6) 510 (28.0) 816 (28.6)
 Antidepressant 228 (22.1) 369 (20.2) 597 (20.9)
 NSAID 205 (19.8) 314 (17.2) 519 (18.2)
  1. Clinical characteristics evaluated during the preindex period (January 1 to December 31, 2012)
  2. AML acute myeloid leukemia, IV intravenous, MM multiple myeloma, NSAID nonsteroidal anti-inflammatory drug, PV polycythemia vera
  3. aIncludes antihypertensives, statins, antidiabetic medications, anticoagulants, antiplatelet medications, and other lipid-lowering medications